Safety of JAK inhibitors versus other biologic therapies following anti-TNF failure in patients with rheumatoid arthritis
In RA patients with inadequate response to TNFis, JAKis and OMA showed comparable safety profiles over 24 months. Serious AEs were numerically higher with OMA; herpes zoster was more frequent with JAKis. No new significant safety signals emerged.
Authors
- Francesca Frizzera (ORCID: https://orcid.org/0000-0002-0611-5605)
- Mariangela Salvato (ORCID: https://orcid.org/0009-0005-5809-6716)
- Alessandro Giollo (ORCID: https://orcid.org/0000-0001-9355-7673)
- Andrea Doria (ORCID: https://orcid.org/0000-0003-0548-4983)
- Roberta Ramonda (ORCID: https://orcid.org/0000-0002-9683-8873)
- Margherita Zen (ORCID: https://orcid.org/0000-0003-0835-1406)
- Lorenzo Di Luozzo
- Kiren Khalid
Institutions
- University of Padua (IT)
Publication Details
- Journal
- Arthritis Research & Therapy
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1186/s13075-025-03686-6
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00